



Evaluation of Postoperative Prognosis on Carotid Endarterectomy: Single Center Experience

Murat ZAIMOGLU¹, Baran Can ALPERGIN¹, Emre Bahir METE¹, Ozgur ORHAN¹, Omer Mert OZPISKIN¹, Melih BOZKURT², Umit EROGLU¹

¹Ankara University, Faculty of Medicine, Department of Neurosurgery, Ankara, Türkiye

²Arel University, Faculty of Medicine, Department of Neurosurgery, Istanbul, Türkiye

Corresponding author: Umit EROGLU ✉ umitkovikeroglu@hotmail.com

ABSTRACT

AIM: To determine the prognostic value of routine hematological indices in patients undergoing carotid endarterectomy (CEA).

MATERIAL and METHODS: As a retrospective single center study, we measured the systemic immune inflammation index (SII) and other systemic inflammatory parameters to estimate the morbidity and mortality of patients undergoing CEA. These parameters include inflammatory markers which are included in routine preoperative haematologic tests like complete blood count (CBC).

RESULTS: After the analysis of the collected datas from 72 patients, the results showed that inflammatory indices were significantly different in patients with different clinical courses.

CONCLUSION: Inflammatory parameters calculated from routine preoperative hematologic parameters proved to be important predictive parameters that can be used in morbidity/mortality estimation of patients scheduled for CEA.

KEYWORDS: Carotid artery, Stenosis, Cerebrovascular, Endarterectomy

INTRODUCTION

Despite the advances in treatment strategies, carotid artery atherosclerosis remains a major cause of stroke and a prominent contributor to overall mortality and morbidity (21,32,44). Carotid artery stenosis accounts for approximately 30% of all cases of stroke (4). The estimated prevalence of carotid artery stenosis in the age group of 30–70 years is 1.8% in males and 1.2% in females (41). Atherosclerotic stenosis of cervical segment of the internal carotid artery is present in approximately 1%–2% of the general adult population; however, it affects more than 10% of individuals between the ages of 60 and 79 years (29,40).

One option for treating the carotid artery stenosis is carotid endarterectomy (CEA) while the other is being carotid artery stenting (CAS). These two vascular treatments recommended for mitigating the risk of major stroke and disability (1,5). CEA

was first reported by Eascott and colleagues in 1954 (15). Over the last 60 years, the techniques for CEA have remarkably evolved (8,30,34). Essentially, CEA is performed to minimise the risk of stroke by surgically removing the atherosclerotic plaque from both the common carotid artery bifurcation and the internal carotid artery (45). The reported rates of restenosis after endarterectomy vary between 5% and 37%, depending on the definition of restenosis and the follow-up period (11,24). Local and systemic inflammatory responses, the presence of risk factors (such as obesity, and dyslipidemia and smoking), and the characteristics of atherosclerotic plaques are the main parameters influencing post-endarterectomy restenosis (6,18,20,35,36).

The key role of atherosclerotic-inflammatory processes in the pathogenesis of carotid stenosis and the ability to readily measure the inflammatory markers using routine

hematological indices have introduced a new perspective on post-endarterectomy prognosis. Inflammatory markers such as blood cell counts and also ratios such as platelet-to-lymphocyte ratio (PLR), or the systemic immune inflammation index (SII) are associated with vascular events (12,22,46), including carotid atherosclerosis (9,36), and cancer prognosis (17,33,43,53).

This study evaluates the value of the SII in predicting post-carotid endarterectomy stroke and mortality.

■ MATERIAL and METHODS

This study is performed under the regulations of the institutional research committee (Date: 02/11/2023, Decision Number: i09-643-23).

Study Design

We reviewed a total of 83 patients retrospectively who underwent carotid endarterectomy between 2017 and 2022 in a tertiary academic care unit. All patients were aged > 18 years, symptomatic, and had at least 50% stenosis. 11 patients were excluded due to active tumors, infection, rheumatological-hematological diseases, or a previous history of CEA. The remaining 72 patients were included and analyzed.

Epidemiologic data as age, sex, and hospitalization period were extracted from the hospital's electronic database. Risk factors, comorbidities, the degree of stenosis, and the side of stenosis were documented.

Inflammatory Markers

Data regarding the following indices were extracted from the laboratory tests: complete blood count including cells of lymphocytes, neutrophil, and platelet. Systemic immune inflammation index (SII), blood cell counts and systemic inflammatory response index (SIRI) were calculated using the following formulae.

$$SII = (\text{neutrophils} \times \text{platelets}) / \text{lymphocytes}$$

$$SIRI = (\text{monocytes} \times \text{platelets}) / \text{lymphocytes}$$

CEA Protocol

Patients underwent CEA under general anesthesia using the classical method, encompassing the preparation of the common, external, and internal carotid arteries, followed by clamping of all three arteries. Prior to clamping, 5000 IU of intravenous heparin was administered. Subsequently, CEA was performed through a longitudinal arteriotomy, which included the removal of atherosclerotic plaques. The excised plaque was then sent for histological evaluation. Finally, arterial reconstruction was carried out using 6-0 Prolene sutures and intradermal stitches (Ethicon, Norderstedt, Germany).

Primary Endpoint and Follow-up

Patients were retrospectively reviewed at least one year look-back and medical histories were collected together with clinical outpatient examinations were conducted. Any occurrence of stroke and/or mortality during this timeframe was documented. Postoperative morbidity and mortality were the main endpoints of this study. We defined stroke as a neurological

deficit that persisted for more than 24 hours. Major adverse cardiovascular and cerebrovascular events (MACCE) included mortality, stroke, and myocardial infarction.

Statistical Analysis

The study universe was divided into three main groups (T1, T2, and T3) based on tertiles of SII level at admission. Baseline characteristics were compared among these three groups. Statistical analyses were conducted for the observed mortality, stroke, and MACCE within each sub-group.

The SPSS 22.0 software program for Windows has been utilised for statistical analyses. Categorical variables were expressed as frequency and differences between groups were analysed by using the Chi-Square Test. Continuous variables were expressed as median and mean \pm standard deviation. Inter-group differences were assessed with Kruskal-Wallis test; p values <0.05 were considered as statistically significant.

■ RESULTS

The study included 72 patients (35 female, 37 male; median age: 71 years) who underwent CEA. Clinically characteristics of the patients categorized according to their SII levels are presented in Table I.

Patients in T2 were significantly younger than patients in the T1 group ($p=0.015$). There were not any statistically significant inter-group differences with respect to gender. When groups were examined based on ipsilateral stenosis, the proportion of patients with the stenosis of 70%–89% in the T2 group was higher than T1, while the proportion of patients with with a stenosis of 50%–69% in the T1 group was remarkably higher than that in T2 ($p=0.020$). Hyperlipidemia was more frequently observed in the T3 group compared to the T1 ($p=0.020$). Data were statistically insignificant between the groups in terms of contralateral stenosis, body mass index (BMI), diabetes mellitus (DM), hypertension (HT), smoking, previous myocardial infarction, percutaneous coronary intervention (PCI), and coronary artery bypass grafting (CABG).

As one progresses from T1 to T3 among the groups, leukocyte counts ($p=0.001$), neutrophil counts ($p<0.001$), platelet counts ($p=0.001$), monocyte counts ($p=0.001$), and SIRI ($p<0.001$) increased, while the lymphocyte counts ($p<0.001$) decreased.

In Table II, the incidence of in-hospital stroke showed an increasing trend from T1 to T3, but the pattern was statistically insignificant due to only three cases. Regarding long-term outcomes, the rates of stroke ($p=0.005$), MACCE ($p=0.001$), and death ($p=0.002$) increased from T1 to T3, and higher SII levels were associated with a higher incidence.

■ DISCUSSION

Atherosclerosis is a major cause of cerebrovascular disease associated mortality. Inflammatory process is a pivotal step in the pathogenesis of atherosclerosis and significantly contributes to the progression of these diseases (28). Atherosclerosis is characterized by the accumulation of lipids, proliferation of smooth muscle cells plus local inflammation. Also, immune system play a pivotal role in this cascade (10).

Table I: Baseline Characteristics of Patients Stratified by Systemic Immune-Inflammation index Tertiles

	T1	T2	T3	p-value
	SII < 419	419 <SII <696	SII > 696	
	n = 24	n = 24	n = 24	
Age (Mean ± SD) (years)	72.54 ± 5.69	66.92 ± 7.07	71.25 ± 8.59	0.015
Sex, female, n (%)	10	13	12	0.566
Stenosis % ipsilateral				
%50–69	3	13	9	0.020
%70–89	16	7	13	
>%90	5	4	2	
ICA stenosis >70%, contralateral	0	1	2	0.768
Body mass index (kg/m ²)				
<18.5	0	0	0	0.676
18.5–24.9	5	5	6	
25–29.9	11	16	11	
>30	8	3	7	
Diabetes mellitus	13	13	16	0.383
Hypertension	18	17	19	0.741
Hyperlipidemia	2	7	9	0.020
Smoking	9	12	8	0.770
Previous myocardial infarction	8	9	10	0.554
Previous PCI	7	7	10	0.362
Previous CABG	2	2	7	0.092
Laboratory parameters				
White blood cell count/μL	7.65 ± 2.47	7.20 ± 1.20	9.38 ± 3.33	0.001
Monocyte count, cells/μL	0.68 ± 0.34	0.59 ± 0.10	2.91 ± 10.25	0.001
Neutrophil count, cells/μL	3.96 ± 0.71	4.32 ± 0.82	7.01 ± 3.08	<0.001
Lymphocyte count, cells/μL	2.82 ± 1.63	2.05 ± 0.46	1.73 ± 0.49	<0.001
Platelet count, cells/μL	222.08 ± 55.09	269.21 ± 55.87	283.17 ± 47.65	0.001
Systemic immune inflammation index (SII)	339.25 ± 91.39	564.00 ± 83.83	1390.44 ± 1410.97	
Systemic inflammatory response index (SIRI)	0.01 ± 0.005	0.01 ± 0.005	0.07 ± 0.227	<0.001

ICA: Internal carotid artery, **PCI:** Percutaneous coronary intervention, **CABG:** Coronary artery bypass grafting.

Table II: In-Hospital and Long-Term Outcomes According to SII Tertiles

	T1	T2	T3	p*
In-hospital outcome, n (%)				
Stroke	0	1	2	0.768
Long-term outcomes, n (%)				
Stroke	1	1	8	0.005
All-cause death	2	3	11	0.002
MACCE	3	4	19	0.001

SII: Systemic immune-inflammation index; **MACCE:** major adverse cardiac and cerebrovascular events. *Fisher's exact test.

Several studies have highlighted the involvement of neutrophils and lymphocytes in the adverse outcomes of patients with coronary artery disease through the progression of coronary atherosclerotic plaques (14,16,27,38,42). Furthermore, various inflammatory markers are associated with the restenosis or neurological complications following CEA or carotid stenting, as well as with an unfavorable prognosis in acute ischemic stroke (3,7,13,20,23,39).

We investigated SII levels in patients who underwent CEA. The SII was initially introduced to assess the immune-inflammatory status and evaluate morbidity and mortality risk in cancer patients. SII is calculated using the platelet, neutrophil, and lymphocyte counts and is considered as a modification of the platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lympho-

cyte ratio (NLR) (47,50-52). Several studies have documented the prognostic value of SII in cardiovascular and cerebrovascular diseases (26,48). However, as pointed out, only one previous study has specifically assessed its potential as a prognostic indicator in patients who have undergone CEA (49).

Atherogenesis is a chronic inflammatory process involving an important interaction of damaged arterial wall cells, inflammatory cells, and cholesterol (27,31,38). Similar to that observed in coronary arteries, intimal carotid plaques are formed by the infiltration of inflammatory cells associated with a central lipid core covered by a fibrin cap (38). The development of lipid plaques and their subsequent expansion into the arterial lumen typically culminates in carotid artery stenosis, the potential for plaque rupture, atherothrombosis, and eventual distal embolization.

Neutrophils play a pivotal role in all atherosclerotic processes, including plaque development, remodeling, rupture, and reperfusion injury (19). They are among the initial inflammatory cells involved in arterial plaques, attracting leukocytes and promoting foam cell formation (25). Due to widespread inflammation and the redistribution of lymphoid cells, a decreased lymphocyte count is often associated with immune system depression and cardiovascular disorders (37). Increased platelet counts, levels of inflammatory mediators, platelet activation, a prothrombotic state, and a thrombus formation rich in platelets within atherosclerotic plaques can contribute to worse outcomes (2).

CONCLUSION

This study indicates that routine hematological indices can provide valuable prognostic insights in patients undergoing CEA. Elevated SII levels are shown to have increased risk of stroke, mortality, and MACE in CEA patients. This index provides a simple and easy-to-apply method in clinics engaged in CEA.

Declarations

Funding: There is no funding to report.

Availability of data and materials: The datasets generated and/or analyzed during the current study are available from the corresponding author by reasonable request.

Disclosure: All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers; bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.

AUTHORSHIP CONTRIBUTION

Study conception and design: MZ, BCA

Data collection: EBM, OO, OMO

Analysis and interpretation of results: MZ, BCA

Draft manuscript preparation: MZ, BCA, OO

Critical revision of the article: MZ, UE

Other (study supervision, fundings, materials, etc...): MB, EBM

All authors (MZ, BCA, EBM, OO, OMO, MB, UE) reviewed the results and approved the final version of the manuscript.

REFERENCES

1. Aboyans V, Ricco JB, Bartelink MEL, Bjorck M, Brodmann M, Cohnert T, Collet JP, Czerny M, De Carlo M, Debus S, Espinola-Klein C, Kahan T, Kownator S, Mazzolai L, Naylor AR, Roffi M, Rother J, Sprynger M, Tendera M, Tepe G, Venermo M, Vlachopoulos C, Desormais I, Group ESCSD: 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering athero-sclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries Endorsed by: the European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). *Eur Heart J* 39:763-816, 2018
2. Balta S, Ozturk C: The platelet-lymphocyte ratio: A simple, inexpensive and rapid prognostic marker for cardiovascular events. *Platelets* 26:680-681, 2015. <https://doi.org/10.3109/09537104.2014.979340>
3. Bao X, Zhou G, Xu W, Liu X, Ye Z, Jiang F: Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio: Novel markers for the diagnosis and prognosis in patients with restenosis following CAS. *Biomark Med* 14:271-282, 2020. <https://doi.org/10.2217/bmm-2019-0155>
4. Barnett HJ, Gunton RW, Eliasziw M, Fleming L, Sharpe B, Gates P, Meldrum H: Causes and severity of ischemic stroke in patients with internal carotid artery stenosis. *JAMA* 283:1429-1436, 2000. <https://doi.org/10.1001/jama.283.11.1429>
5. Bonati LH, Jansen O, de Borst GJ, Brown MM: Management of atherosclerotic extracranial carotid artery stenosis. *Lancet Neurol* 21:273-283, 2022. [https://doi.org/10.1016/S1474-4422\(21\)00359-8](https://doi.org/10.1016/S1474-4422(21)00359-8)
6. Brunelli N, Altamura C, Costa CM, Altavilla R, Palazzo P, Maggio P, Marcosano M, Vernieri F: Carotid artery plaque progression: Proposal of a new predictive score and role of carotid intima-media thickness. *Int J Environ Res Public Health* 19:758, 2022. <https://doi.org/10.3390/ijerph19020758>
7. Casanova N, Diaz-Duran C, Nieto L, Llorca C, Elosua R, Clara A: Predictive value of complete blood count-derived inflammatory markers for 5-year survival after carotid endarterectomy: Implications for practice. *Angiology* 73:675-681, 2022. <https://doi.org/10.1177/00033197211067581>
8. Cooley DA, Al-Naaman YD, Carton CA: Surgical treatment of arteriosclerotic occlusion of common carotid artery. *J Neurosurg* 13:500-506, 1956. <https://doi.org/10.3171/jns.1956.13.5.0500>

9. Corriere T, Di Marca S, Cataudella E, Pulvirenti A, Alaimo S, Stancanelli B, Malatino L: Neutrophil-to-Lymphocyte Ratio is a strong predictor of atherosclerotic carotid plaques in older adults. *Nutr Metab Cardiovasc Dis* 28:23-27, 2018. <https://doi.org/10.1016/j.numecd.2017.10.022>
10. Cybulsky MI, Gimbrone MA Jr: Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. *Science* 251:788-791, 1991. <https://doi.org/10.1126/science.1990440>
11. DeGroot RD, Lynch TG, Jamil Z, Hobson RW 2nd: Carotid Restenosis: Long-term noninvasive follow-up after carotid endarterectomy. *Stroke* 18:1031-1036, 1987. <https://doi.org/10.1161/01.STR.18.6.1031>
12. Dentali F, Nigro O, Squizzato A, Gianni M, Zuretti F, Grandi AM, Guasti L: Impact of neutrophils to lymphocytes ratio on major clinical outcomes in patients with acute coronary syndromes: A systematic review and meta-analysis of the literature. *Int J Cardiol* 266:31-37, 2018. <https://doi.org/10.1016/j.ijcard.2018.02.116>
13. Deser SB, Yucel SM, Demirag MK, Guclu MM, Kolbaker F, Keceligil HT: The association between platelet/lymphocyte ratio, neutrophil/lymphocyte ratio, and carotid artery stenosis and stroke following carotid endarterectomy. *Vascular* 27:604-611, 2019. <https://doi.org/10.1177/1708538119847390>
14. Duffy BK, Gurm HS, Rajagopal V, Gupta R, Ellis SG, Bhatt DL: Usefulness of an elevated neutrophil to lymphocyte ratio in predicting long-term mortality after percutaneous coronary intervention. *Am J Cardiol* 97:993-996, 2006. <https://doi.org/10.1016/j.amjcard.2005.10.034>
15. Eastcott HH, Pickering GW, Rob CG: Reconstruction of internal carotid artery in a patient with intermittent attacks of hemiplegia. *Lancet* 267:994-996, 1954. [https://doi.org/10.1016/S0140-6736\(54\)90544-9](https://doi.org/10.1016/S0140-6736(54)90544-9)
16. Gibson PH, Croal BL, Cuthbertson BH, Small GR, Ifezulike AI, Gibson G, Jeffrey RR, Buchan KG, El-Shafei H, Hillis GS: Preoperative neutrophil-lymphocyte ratio and outcome from coronary artery bypass grafting. *Am Heart J* 154:995-1002, 2007. <https://doi.org/10.1016/j.ahj.2007.06.043>
17. Guo J, Fang J, Huang X, Liu Y, Yuan Y, Zhang X, Zou C, Xiao K, Wang J: Prognostic role of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in prostate cancer: A meta-analysis of results from multivariate analysis. *Int J Surg* 60:216-223, 2018. <https://doi.org/10.1016/j.ijsu.2018.11.020>
18. Herder M, Johnsen SH, Arntzen KA, Mathiesen EB: Risk factors for progression of carotid intima-media thickness and total plaque area: A 13-year follow-up study: The Tromso Study. *Stroke* 43:1818-1823, 2012. <https://doi.org/10.1161/STROKEAHA.111.646596>
19. Ionita MG, van den Borne P, Catanzariti LM, Moll FL, de Vries JP, Pasterkamp G, Vink A, de Kleijn DP: High neutrophil numbers in human carotid atherosclerotic plaques are associated with characteristics of rupture-prone lesions. *Arterioscler Thromb Vasc Biol* 30:1842-1848, 2010. <https://doi.org/10.1161/ATVBAHA.110.209296>
20. King AH, Kim AH, Kwan S, Lee J, Schmaier AH, Kumins NH, Harth KC, Wong VL, Colvard BD, Kashyap VS, Cho JS: Elevated neutrophil to lymphocyte ratio is associated with worse outcomes after carotid endarterectomy in asymptomatic patients. *J Stroke Cerebrovasc Dis* 30:106120, 2021. <https://doi.org/10.1016/j.jstrokecerebrovasdis.2021.106120>
21. Kopczak A, Schindler A, Sepp D, Bayer-Karpinska A, Malik R, Koch ML, Zeller J, Strecker C, Janowitz D, Wollenweber FA, Hempel JM, Boeckh-Behrens T, Cyran CC, Helck A, Harloff A, Zie-mann U, Poli S, Poppert H, Saam T, Dichgans M: Complicated carotid artery plaques and risk of recurrent ischemic stroke or TIA. *J Am Coll Cardiol* 79:2189-2199, 2022. <https://doi.org/10.1016/j.jacc.2022.03.376>
22. Kurtul A, Ornek E: Platelet to lymphocyte ratio in cardiovascular diseases: A systematic review. *Angiology* 70:802-818, 2019. <https://doi.org/10.1177/0003319719845186>
23. Lattanzi S, Norata D, Broggi S, Meletti S, Switonska M, Slomka A, Silvestrini M: Neutrophil-to-lymphocyte ratio predicts early neurological deterioration after endovascular treatment in patients with ischemic stroke. *Life (Basel)* 12:1415, 2022. <https://doi.org/10.3390/life12091415>
24. Lattimer CR, Burnand KG: Recurrent carotid stenosis after carotid endarterectomy. *Br J Surg* 84:1206-1219, 1997. <https://doi.org/10.1046/j.1365-2168.1997.02849.x>
25. Leclercq A, Houard X, Philippe M, Ollivier V, Sebbag U, Meilhac O, Michel JB: Involvement of intraplaque hemorrhage in atherothrombosis evolution via neutrophil protease enrichment. *J Leukoc Biol* 82:1420-1429, 2007. <https://doi.org/10.1189/jlb.1106671>
26. Li LH, Chen CT, Chang YC, Chen YJ, Lee IH, How CK: Prognostic role of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and systemic immune inflammation index in acute ischemic stroke: A STROBE-compliant retrospective study. *Medicine (Baltimore)* 100:e26354, 2021. <https://doi.org/10.1097/MD.0000000000026354>
27. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. *Circulation* 105:1135-1143, 2002. <https://doi.org/10.1161/hc0902.104353>
28. Liberale L, Badimon L, Montecucco F, Luscher TF, Libby P, Camici GG: Inflammation, aging, and cardiovascular disease: Jacc review topic of the week. *J Am Coll Cardiol* 79:837-847, 2022. <https://doi.org/10.1016/j.jacc.2021.12.017>
29. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kitt-ner S, Lackland D, Lisabeth L, Marelli A, McDermott MM, Meigs J, Mozaffarian D, Mussolino M, Nichol G, Roger VL, Rosamond W, Sacco R, Sorlie P, Stafford R, Thom T, Wasserthiel-Smoller S, Wong ND, Wylie-Rosett J, American Heart Association Statistics C, Stroke Statistics S: Executive summary: Heart disease and stroke statistics--2010 update: A report from the American Heart Association. *Circulation* 121:948-954, 2010. <https://doi.org/10.1161/CIRCULATIONAHA.109.192666>
30. Loftus CM: Technical aspects of carotid endarterectomy with Hemashield patch graft. *Neurol Med Chir (Tokyo)* 37:805-818, 1997. <https://doi.org/10.2176/nmc.37.805>

31. Lulis AJ: Atherosclerosis. *Nature* 407:233-241, 2000. <https://doi.org/10.1038/35025203>
32. Mac Grory B, Emmer BJ, Roosendaal SD, Zagzag D, Yaghi S, Nassek E: Carotid web: An oc-cult mechanism of embolic stroke. *J Neurol Neurosurg Psychiatry* 91:1283-1289, 2020. <https://doi.org/10.1136/jnnp-2020-323938>
33. Moon G, Noh H, Cho JJ, Lee JJ, Han A: Prediction of late recurrence in patients with breast cancer: Elevated neutrophil to lymphocyte ratio (NLR) at 5 years after diagnosis and late recurrence. *Breast Cancer* 27:54-61, 2020. <https://doi.org/10.1007/s12282-019-00994-z>
34. Murphey F, Miller JH: Carotid insufficiency: Diagnosis and surgical treatment; a report of twenty-one cases. *J Neurosurg* 16:1-23, 1959. <https://doi.org/10.3171/jns.1959.16.1.0001>
35. Nguyen DT, Berczi A, Nyarady BB, Szonyi A, Philippovich M, Dosa E: Short- and mid-term outcomes of stenting in patients with isolated distal internal carotid artery stenosis or post-surgical restenosis. *J Clin Med* 11:5640, 2022. <https://doi.org/10.3390/jcm11195640>
36. Niculescu R, Russu E, Arbanasi EM, Kaller R, Arbanasi EM, Melinte RM, Cosarca CM, Cocuz IG, Sabau AH, Tinca AC, Stoian A, Vunvulea V, Muresan AV, Cotoi OS: Carotid plaque features and inflammatory biomarkers as predictors of restenosis and mortality following carotid endarterectomy. *Int J Environ Res Public Health* 19:13934, 2022. <https://doi.org/10.3390/ijerph192113934>
37. Ommen SR, Hodge DO, Rodeheffer RJ, McGregor CG, Thomson SP, Gibbons RJ: Predictive power of the relative lymphocyte concentration in patients with advanced heart failure. *Circulation* 97:19-22, 1998. <https://doi.org/10.1161/01.CIR.97.1.19>
38. Ross R: Atherosclerosis-an inflammatory disease. *N Engl J Med* 340:115-126, 1999. <https://doi.org/10.1056/NEJM199901143400207>
39. Sadeghi F, Sarkady F, Zsori KS, Szegedi I, Orban-Kalmanti R, Szekeley EG, Vasas N, Berenyi E, Csiba L, Bagoly Z, Shemirani AH: High neutrophil-lymphocyte ratio and low lymphocyte-monocyte ratio combination after thrombolysis is a potential predictor of poor functional out-come of acute ischemic stroke. *J Pers Med* 12:1221, 2022. <https://doi.org/10.3390/jpm12081221>
40. Schindler A, Schinner R, Altaf N, Hosseini AA, Simpson RJ, Esposito-Bauer L, Singh N, Kwee RM, Kurosaki Y, Yamagata S, Yoshida K, Miyamoto S, Maggisano R, Moody AR, Poppert H, Kooi ME, Auer DP, Bonati LH, Saam T: Prediction of stroke risk by detection of hemorrhage in carotid plaques: Meta-analysis of individual patient data. *JACC Cardiovasc Imaging* 13:395-406, 2020. <https://doi.org/10.1016/j.jcmg.2019.03.028>
41. Song P, Fang Z, Wang H, Cai Y, Rahimi K, Zhu Y, Fowkes FGR, Fowkes FJL, Rudan I: Global and regional prevalence, burden, and risk factors for carotid atherosclerosis: A systematic re-view, meta-analysis, and modelling study. *Lancet Glob Health* 8:e721-e729, 2020. [https://doi.org/10.1016/S2214-109X\(20\)30117-0](https://doi.org/10.1016/S2214-109X(20)30117-0)
42. Tamhane UU, Aneja S, Montgomery D, Rogers EK, Eagle KA, Gurm HS: Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome. *Am J Cardiol* 102:653-657, 2008. <https://doi.org/10.1016/j.amjcard.2008.05.006>
43. Tomita M, Ayabe T, Maeda R, Nakamura K: Systemic immune-inflammation index predicts survival of patients after curative resection for non-small cell lung cancer. *In Vivo* 32:663-667, 2018. <https://doi.org/10.21873/invivo.11291>
44. Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, Boehme AK, Bux-ton AE, Carson AP, Commodore-Mensah Y, Elkind MSV, Evenson KR, Eze-Nliam C, Ferguson JF, Generoso G, Ho JE, Kalani R, Khan SS, Kissela BM, Knutson KL, Levine DA, Lewis TT, Liu J, Loop MS, Ma J, Mussolino ME, Navaneethan SD, Perak AM, Poudel R, Rezk-Hanna M, Roth GA, Schroe-der EB, Shah SH, Thacker EL, VanWagner LB, Virani SS, Voecks JH, Wang NY, Yaffe K, Martin SS: Heart disease and stroke statistics-2022 update: A report from the american heart association. *Circulation* 145:e153-e639, 2022. <https://doi.org/10.1161/CIR.0000000000001052>
45. Uno M, Takai H, Yagi K, Matsubara S: Surgical technique for carotid endarterectomy: Current methods and problems. *Neurol Med Chir (Tokyo)* 60:419-428, 2020. <https://doi.org/10.2176/nmc.ra.2020-0111>
46. Xiang F, Chen R, Cao X, Shen B, Liu Z, Tan X, Ding X, Zou J: Monocyte/lymphocyte ratio as a better predictor of cardiovascular and all-cause mortality in hemodialysis patients: A prospec-tive cohort study. *Hemodial Int* 22:82-92, 2018. <https://doi.org/10.1111/hdi.12549>
47. Yang R, Chang Q, Meng X, Gao N, Wang W: Prognostic value of Systemic immune-inflammation index in cancer: A meta-analysis. *J Cancer* 9:3295-3302, 2018. <https://doi.org/10.7150/jca.25691>
48. Yang YL, Wu CH, Hsu PF, Chen SC, Huang SS, Chan WL, Lin SJ, Chou CY, Chen JW, Pan JP, Charng MJ, Chen YH, Wu TC, Lu TM, Huang PH, Cheng HM, Huang CC, Sung SH, Lin YJ, Leu HB: Systemic immune-inflammation index (SII) predicted clinical outcome in patients with coronary artery disease. *Eur J Clin Invest* 50:e13230, 2020. <https://doi.org/10.1111/eci.13230>
49. Yuksel A, Velioglu Y, Korkmaz UTK, Deser SB, Topal D, Badem S, Taner T, Ucaroglu ER, Kahraman N, Demir D: Systemic immune-inflammation index for predicting poor outcome after carotid endarterectomy: A novel hematological marker. *Vascular* 32:565-572, 2024. <https://doi.org/10.1177/17085381221141476>
50. Zhang Y, Chen B, Wang L, Wang R, Yang X: Systemic immune-inflammation index is a promising noninvasive marker to predict survival of lung cancer: A meta-analysis. *Medicine (Bal-timore)* 98:e13788, 2019. <https://doi.org/10.1097/MD.00000000000013788>
51. Zhang Y, Lin S, Yang X, Wang R, Luo L: Prognostic value of pretreatment systemic im-mune-inflammation index in patients with gastrointestinal cancers. *J Cell Physiol* 234:5555-5563, 2019. <https://doi.org/10.1002/jcp.27373>
52. Zhong JH, Huang DH, Chen ZY: Prognostic role of systemic immune-inflammation index in solid tumors: A systematic review and meta-analysis. *Oncotarget* 8:75381-75388, 2017. <https://doi.org/10.18632/oncotarget.18856>
53. Zhou X, Du Y, Huang Z, Xu J, Qiu T, Wang J, Wang T, Zhu W, Liu P: Prognostic value of PLR in various cancers: A meta-analysis. *PLoS One* 9:e101119, 2014. <https://doi.org/10.1371/journal.pone.0101119>